🎉 M&A multiples are live!
Check it out!

Eton Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Eton Pharmaceuticals and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Eton Pharmaceuticals Overview

About Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.


Founded

2017

HQ

United States of America
Employees

30

Website

etonpharma.com

Financials

LTM Revenue $49.0M

LTM EBITDA $5.1M

EV

$383M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Eton Pharmaceuticals Financials

Eton Pharmaceuticals has a last 12-month revenue of $49.0M and a last 12-month EBITDA of $5.1M.

In the most recent fiscal year, Eton Pharmaceuticals achieved revenue of $39.0M and an EBITDA of -$1.5M.

Eton Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Eton Pharmaceuticals valuation multiples based on analyst estimates

Eton Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $31.6M $39.0M XXX XXX XXX
Gross Profit $14.3M $21.1M XXX XXX XXX
Gross Margin 45% 54% XXX XXX XXX
EBITDA -$0.3M -$1.5M XXX XXX XXX
EBITDA Margin -1% -4% XXX XXX XXX
Net Profit -$9.0M -$0.9M XXX XXX XXX
Net Margin -29% -2% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Eton Pharmaceuticals Stock Performance

As of April 15, 2025, Eton Pharmaceuticals's stock price is $14.

Eton Pharmaceuticals has current market cap of $368M, and EV of $383M.

See Eton Pharmaceuticals trading valuation data

Eton Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$383M $368M XXX XXX XXX XXX $0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Eton Pharmaceuticals Valuation Multiples

As of April 15, 2025, Eton Pharmaceuticals has market cap of $368M and EV of $383M.

Eton Pharmaceuticals's trades at 7.8x LTM EV/Revenue multiple, and 74.5x LTM EBITDA.

Analysts estimate Eton Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Eton Pharmaceuticals and 10K+ public comps

Eton Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $383M XXX XXX XXX
EV/Revenue 9.8x XXX XXX XXX
EV/EBITDA -263.9x XXX XXX XXX
P/E -96.2x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -42.3x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Eton Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Eton Pharmaceuticals Valuation Multiples

Eton Pharmaceuticals's NTM/LTM revenue growth is 73%

Eton Pharmaceuticals's revenue per employee for the last fiscal year averaged $1.3M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Eton Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Eton Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Eton Pharmaceuticals and other 10K+ public comps

Eton Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 23% XXX XXX XXX XXX
EBITDA Margin -4% XXX XXX XXX XXX
EBITDA Growth 399% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 69% XXX XXX XXX XXX
Revenue per Employee $1.3M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 58% XXX XXX XXX XXX
R&D Expenses to Revenue 8% XXX XXX XXX XXX
Opex to Revenue 67% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Eton Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Eton Pharmaceuticals M&A and Investment Activity

Eton Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Eton Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Eton Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Eton Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Eton Pharmaceuticals

When was Eton Pharmaceuticals founded? Eton Pharmaceuticals was founded in 2017.
Where is Eton Pharmaceuticals headquartered? Eton Pharmaceuticals is headquartered in United States of America.
How many employees does Eton Pharmaceuticals have? As of today, Eton Pharmaceuticals has 30 employees.
Who is the CEO of Eton Pharmaceuticals? Eton Pharmaceuticals's CEO is Mr. Sean E. Brynjelsen.
Is Eton Pharmaceuticals publicy listed? Yes, Eton Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Eton Pharmaceuticals? Eton Pharmaceuticals trades under ETON ticker.
When did Eton Pharmaceuticals go public? Eton Pharmaceuticals went public in 2018.
Who are competitors of Eton Pharmaceuticals? Similar companies to Eton Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Eton Pharmaceuticals? Eton Pharmaceuticals's current market cap is $368M
What is the current revenue of Eton Pharmaceuticals? Eton Pharmaceuticals's last 12-month revenue is $49.0M.
What is the current EBITDA of Eton Pharmaceuticals? Eton Pharmaceuticals's last 12-month EBITDA is $5.1M.
What is the current EV/Revenue multiple of Eton Pharmaceuticals? Current revenue multiple of Eton Pharmaceuticals is 7.8x.
What is the current EV/EBITDA multiple of Eton Pharmaceuticals? Current EBITDA multiple of Eton Pharmaceuticals is 74.5x.
What is the current revenue growth of Eton Pharmaceuticals? Eton Pharmaceuticals revenue growth between 2023 and 2024 was 23%.
Is Eton Pharmaceuticals profitable? Yes, Eton Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.